Clinical trial
Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With…
NCT00142467 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00142467 |
|---|---|
| Title | Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma |
| Official title | Phase II Study of Gemcitabine, Oxaliplatin in Combination With Bevacizumab (Avastin) in Patients With Hepatocellular Carcinoma |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Dana-Farber Cancer Institute Beth Israel Deaconess Medical Center Brigham and Women's Hospital Genentech, Inc. Industry Sanofi-Synthelabo Eli Lilly and Company |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatocellular Carcinoma |
| Intervention type | Drug |
| Interventions | Gemcitabine, Oxaliplatin, Bevacizumab |
| Enrollment | 33 |
| Start date | Apr 1, 2004 |
| Primary completion | Aug 1, 2006 |
| Completion | Jun 1, 2011 |
| First posted | Sep 2, 2005 |
| Last update posted | Mar 18, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: